Home
>
US Stocks
>
DermTech Inc

DermTech Inc (DMTK)

$2.51

+0.13

(+5.46%)▲

Market is closed - opens 7 PM, 02 Jun 2023

Insights on DermTech Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 4.23M → 2.99M (in $), with an average decrease of 15.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -28.22M → -31.27M (in $), with an average decrease of 10.8% per quarter

  • Vs IDXX

    In the last 1 year, Idexx Laboratories, Inc. has given 21.6% return, outperforming this stock by 84.3%

  • Vs IDXX

    In the last 3 years, Idexx Laboratories, Inc. has given 48.5% return, outperforming this stock by 129.6%

Performance

  • $2.31
    $2.51
    $2.51
    downward going graph

    7.97%

    Downside

    Day's Volatility :7.97%

    Upside

    0.0%

    downward going graph
  • $1.55
    $8.93
    $2.51
    downward going graph

    38.25%

    Downside

    52 Weeks Volatility :82.64%

    Upside

    71.89%

    downward going graph

Returns

PeriodDermTech IncSector (Health Care)Index (Russel 2000)
3 Months
-33.95%
0.7%
-7.0%
6 Months
-6.69%
-7.9%
-6.5%
1 Year
-62.7%
-2.0%
-6.8%
3 Years
-81.11%
25.4%
24.7%

Highlights

Market Capitalization
74.0M
Book Value
$3.45
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.85
Wall Street Target Price
5.1
Profit Margin
0.0%
Operating Margin TTM
-840.65%
Return On Assets TTM
-36.01%
Return On Equity TTM
-75.85%
Revenue TTM
14.3M
Revenue Per Share TTM
0.47
Quarterly Revenue Growth YOY
-6.5%
Gross Profit TTM
647.0K
EBITDA
-118.3M
Diluted Eps TTM
-3.85
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.75
EPS Estimate Next Year
-2.91
EPS Estimate Current Quarter
-0.91
EPS Estimate Next Quarter
-0.88

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for DermTech Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 103.19%

Current $2.51
Target $5.10

Technicals Summary

Sell

Neutral

Buy

DermTech Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
DermTech Inc
DermTech Inc
-14.19%
-6.69%
-62.7%
-81.11%
-74.77%
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
0.53%
7.93%
21.61%
48.46%
114.73%
Agilent Technologies Inc.
Agilent Technologies Inc.
-13.57%
-25.32%
-9.95%
28.76%
83.43%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-4.49%
-7.75%
-8.9%
48.36%
142.51%
Danaher Corp.
Danaher Corp.
-4.16%
-15.15%
-14.85%
39.37%
128.42%
IQVIA Holdings Inc.
IQVIA Holdings Inc.
7.2%
-8.62%
-9.58%
31.31%
96.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
DermTech Inc
DermTech Inc
NA
NA
NA
-3.75
-0.76
-0.36
0.0
3.45
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
56.2
56.2
7.21
9.69
0.94
0.22
0.0
10.13
Agilent Technologies Inc.
Agilent Technologies Inc.
26.91
26.91
2.36
5.63
0.25
0.1
0.01
18.96
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
33.19
33.19
4.28
23.68
0.14
0.05
0.0
109.55
Danaher Corp.
Danaher Corp.
24.72
24.72
3.24
9.38
0.14
0.06
0.0
68.31
IQVIA Holdings Inc.
IQVIA Holdings Inc.
35.16
35.16
1.48
10.42
0.18
0.05
0.0
31.98
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
DermTech Inc
DermTech Inc
Buy
$74.0M
-74.77%
NA
0.0%
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
Buy
$38.6B
114.73%
56.2
20.38%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$35.3B
83.43%
26.91
19.09%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$196.1B
142.51%
33.19
13.75%
Danaher Corp.
Danaher Corp.
Buy
$169.4B
128.42%
24.72
22.4%
IQVIA Holdings Inc.
IQVIA Holdings Inc.
Buy
$36.5B
96.53%
35.16
7.28%

Institutional Holdings

  • RTW INVESTMENTS, LLC

    8.74%

  • Vanguard Group Inc

    3.88%

  • BlackRock Inc

    1.48%

  • King Luther Capital Management Corp

    0.98%

  • EPIQ PARTNERS, LLC

    0.98%

  • White Pine Capital LLC

    0.83%

Corporate Announcements

  • DermTech Inc Earnings

    DermTech Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. DermTech's mission is to transform dermatology with its non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments.

Organization
DermTech Inc
Employees
278
CEO
Dr. John D. Dobak M.D.
Industry
Finance

Discover More

FAQs